Probing for a deeper understanding of rhabdomyosarcoma

Insights from complementary model systems

Venkatesh P. Kashi, Mark E. Hatley, Rene L. Galindo

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Rhabdomyosarcoma (RMS) is a mesenchymal malignancy composed of neoplastic primitive precursor cells that exhibit histological features of myogenic differentiation. Despite intensive conventional multimodal therapy, patients with high-risk RMS typically suffer from aggressive disease. The lack of directed therapies against RMS emphasizes the need to further uncover the molecular underpinnings of the disease. In this Review, we discuss the notable advances in the model systems now available to probe for new RMS-targetable pathogenetic mechanisms, and the possibilities for enhanced RMS therapeutics and improved clinical outcomes.

Original languageEnglish (US)
Pages (from-to)426-439
Number of pages14
JournalNature Reviews Cancer
Volume15
Issue number7
DOIs
StatePublished - Jul 26 2015

Fingerprint

Rhabdomyosarcoma
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Probing for a deeper understanding of rhabdomyosarcoma : Insights from complementary model systems. / Kashi, Venkatesh P.; Hatley, Mark E.; Galindo, Rene L.

In: Nature Reviews Cancer, Vol. 15, No. 7, 26.07.2015, p. 426-439.

Research output: Contribution to journalArticle

@article{54f4fa92af9e480989e0d1b2bd2a451a,
title = "Probing for a deeper understanding of rhabdomyosarcoma: Insights from complementary model systems",
abstract = "Rhabdomyosarcoma (RMS) is a mesenchymal malignancy composed of neoplastic primitive precursor cells that exhibit histological features of myogenic differentiation. Despite intensive conventional multimodal therapy, patients with high-risk RMS typically suffer from aggressive disease. The lack of directed therapies against RMS emphasizes the need to further uncover the molecular underpinnings of the disease. In this Review, we discuss the notable advances in the model systems now available to probe for new RMS-targetable pathogenetic mechanisms, and the possibilities for enhanced RMS therapeutics and improved clinical outcomes.",
author = "Kashi, {Venkatesh P.} and Hatley, {Mark E.} and Galindo, {Rene L.}",
year = "2015",
month = "7",
day = "26",
doi = "10.1038/nrc3961",
language = "English (US)",
volume = "15",
pages = "426--439",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Probing for a deeper understanding of rhabdomyosarcoma

T2 - Insights from complementary model systems

AU - Kashi, Venkatesh P.

AU - Hatley, Mark E.

AU - Galindo, Rene L.

PY - 2015/7/26

Y1 - 2015/7/26

N2 - Rhabdomyosarcoma (RMS) is a mesenchymal malignancy composed of neoplastic primitive precursor cells that exhibit histological features of myogenic differentiation. Despite intensive conventional multimodal therapy, patients with high-risk RMS typically suffer from aggressive disease. The lack of directed therapies against RMS emphasizes the need to further uncover the molecular underpinnings of the disease. In this Review, we discuss the notable advances in the model systems now available to probe for new RMS-targetable pathogenetic mechanisms, and the possibilities for enhanced RMS therapeutics and improved clinical outcomes.

AB - Rhabdomyosarcoma (RMS) is a mesenchymal malignancy composed of neoplastic primitive precursor cells that exhibit histological features of myogenic differentiation. Despite intensive conventional multimodal therapy, patients with high-risk RMS typically suffer from aggressive disease. The lack of directed therapies against RMS emphasizes the need to further uncover the molecular underpinnings of the disease. In this Review, we discuss the notable advances in the model systems now available to probe for new RMS-targetable pathogenetic mechanisms, and the possibilities for enhanced RMS therapeutics and improved clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84933040183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933040183&partnerID=8YFLogxK

U2 - 10.1038/nrc3961

DO - 10.1038/nrc3961

M3 - Article

VL - 15

SP - 426

EP - 439

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 7

ER -